These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35950033)

  • 1. A 16-gene signature associated with homologous recombination deficiency for prognosis prediction in patients with triple-negative breast cancer.
    Wang D; Shi Y; Huang H; Zhao Q; He Y; Su W
    Open Med (Wars); 2022; 17(1):882-896. PubMed ID: 35950033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer.
    Liao G; Jiang Z; Yang Y; Zhang C; Jiang M; Zhu J; Xu L; Xie A; Yan M; Zhang Y; Xiao Y; Li X
    BMC Med; 2021 Sep; 19(1):190. PubMed ID: 34465315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair Deficiency.
    Liao G; Yang Y; Xie A; Jiang Z; Liao J; Yan M; Zhou Y; Zhu J; Hu J; Zhang Y; Xiao Y; Li X
    Front Cell Dev Biol; 2022; 10():845950. PubMed ID: 35281113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
    Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
    Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and Validation of a Prognostic Risk Model for Triple-Negative Breast Cancer Based on Autophagy-Related Genes.
    Yan C; Liu Q; Jia R
    Front Oncol; 2022; 12():829045. PubMed ID: 35186763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
    Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
    Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and validation of a prognostic model based on HRR-related lncRNAs in colon adenocarcinoma.
    Tang X; Lin Y; He J; Luo X; Liang J; Zhu X; Li T
    World J Surg Oncol; 2022 Mar; 20(1):74. PubMed ID: 35264195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multiomics Signature Highlights Alterations Underlying Homologous Recombination Deficiency in Triple-Negative Breast Cancer.
    Su GH; Jiang L; Xiao Y; Zheng RC; Wang H; Jiang YZ; Peng WJ; Shao ZM; Gu YJ; You C
    Ann Surg Oncol; 2022 Oct; 29(11):7165-7175. PubMed ID: 35711018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel immune checkpoint-related gene signature for predicting overall survival and immune status in triple-negative breast cancer.
    Liu J; Ling Y; Su N; Li Y; Tian S; Hou B; Luo S; Zhao L; Shi M
    Transl Cancer Res; 2022 Jan; 11(1):181-192. PubMed ID: 35261895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an ubiquitin-proteasome system signature for predicting prognosis and providing therapeutic guidance for patients with triple-negative breast cancer.
    Chen X; Ren C; Zhou Z; Chen J; Fan X; Li X; Chen J; Zhu J
    J Gene Med; 2024 Jan; 26(1):e3584. PubMed ID: 37605934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency.
    Stecklein SR; Barlow W; Pusztai L; Timms K; Kennedy R; Logan GE; Seitz R; Badve S; Gökmen-Polar Y; Porter P; Linden H; Tripathy D; Hortobagyi GN; Godwin AK; Thompson A; Hayes DF; Sharma P
    JCO Precis Oncol; 2023 Sep; 7():e2300197. PubMed ID: 37972336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Verification of a Prognostic Ferroptosis-Related Gene Model in Triple-Negative Breast Cancer.
    Wu S; Pan R; Lu J; Wu X; Xie J; Tang H; Li X
    Front Oncol; 2022; 12():896927. PubMed ID: 35719954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a Hypoxia-Related Molecular Classification and Hypoxic Tumor Microenvironment Signature for Predicting the Prognosis of Patients with Triple-Negative Breast Cancer.
    Sun X; Luo H; Han C; Zhang Y; Yan C
    Front Oncol; 2021; 11():700062. PubMed ID: 34490098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of potential key genes and pathways predicting pathogenesis and prognosis for triple-negative breast cancer.
    Lv X; He M; Zhao Y; Zhang L; Zhu W; Jiang L; Yan Y; Fan Y; Zhao H; Zhou S; Ma H; Sun Y; Li X; Xu H; Wei M
    Cancer Cell Int; 2019; 19():172. PubMed ID: 31297036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.
    Chai Y; Chen Y; Zhang D; Wei Y; Li Z; Li Q; Xu B
    J Pers Med; 2022 Feb; 12(2):. PubMed ID: 35207810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous recombination deficiency in triple-negative breast cancer: Multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response.
    Kang K; Wu Y; Han C; Wang L; Wang Z; Zhao A
    Comput Biol Med; 2023 May; 158():106836. PubMed ID: 37031511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
    Llop-Guevara A; Loibl S; Villacampa G; Vladimirova V; Schneeweiss A; Karn T; Zahm DM; Herencia-Ropero A; Jank P; van Mackelenbergh M; Fasching PA; Marmé F; Stickeler E; Schem C; Dienstmann R; Florian S; Nekljudova V; Balmaña J; Hahnen E; Denkert C; Serra V
    Ann Oncol; 2021 Dec; 32(12):1590-1596. PubMed ID: 34520831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Insights Into Triple-Negative Breast Cancer Prognosis by Comprehensive Characterization of Aberrant Alternative Splicing.
    Gong S; Song Z; Spezia-Lindner D; Meng F; Ruan T; Ying G; Lai C; Wu Q; Liang Y
    Front Genet; 2020; 11():534. PubMed ID: 32595697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
    Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
    Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.